The aim of the current investigation was to estimate serum IL-17A and Claudin-1 levels in psoriasis, detect their correlation with disease severity, and examine whether they are blood-based candidate biomarkers associated with psoriasis and subtypes. The gene discussed is CLDN1; the disease is psoriasis.